🔥🔥🔥 JOIN OUR STARTUP AMBASSADOR PROGRAM 🔥🔥🔥
    📣 Spread the news & get a PRO membership 3 months for FREE with all features🚀📈💵134 vouchers left • 3 months free
    Home/Investor Database/Synthetic Data
    Focus Area

    Synthetic Data Investors

    CapLink currently tracks 9 verified investors focused on Synthetic Data — a small but growing slice of the global funding landscape.

    The mix is led by VC and PE/Buy-Out. Deal coverage spans Pre-Seed through PE/Buy-out, with the largest concentration at Seed.

    Investor headquarters cluster in Canada, United States, Israel, Spain and Mexico, with activity across 99 countries in total. Ticket sizes range from roughly $250K to $145M, covering early angel cheques through to growth-stage rounds.

    Use the pre-filtered database below to explore every Synthetic Data investor on CapLink, or sign up to unlock contact details, ticket sizes and detailed investment criteria.

    9
    Active investors
    2
    Investor types
    8
    Funding rounds covered
    99
    Countries represented

    Synthetic Data investor database

    9 investors matched for Synthetic Data. Sign up to unlock contact details and full profiles.

    Investor
    The Data Venture logo
    The Data Venture is a venture capital firm specializes in seed stage and startups investments. The firm seeks to invest in deep- tech fields such as decentralization, cryptography and blockchain. It typically invests in Europe. The firm initially invests between €0.5 million ($0.58 million) to €1.5 million ($1.74 million) in data-driven companies. The Data Venture is headquartered in Barcelona, Spain.
    Data Point Capital logo
    At Data Point Capital, we invest in revenue-stage technology companies that are disrupting large markets across both B2B and B2C. We specifically target businesses that are both capital efficient and high growth. As former operators, our experience helps us guide entrepreneurs to realize their vision.
    Frost Data Capital is a venture capital firm specializing in start-up investments, early stage startups, and incubation. It prefers to invest in big data analytics, health technology, and industrials. Frost Data Capital is based in San Juan Capistrano, California.
    MLS Capital logo
    MLS Capital Fund II (MLSCF II), co-managed by Spruce Capital Partners and Xeraya Capital, will invest the funds in a diversified portfolio of biogreentech companies at all stages of development. Biogreentech spans plant and animal agriculture; food, feed, and nutrition; bio-renewable chemicals and materials; and adjacent opportunities along the value chain, including “big data" analytics, robotics, production, harvesting and use of natural resources, and synthetic biology.
    Bedford Bridge logo
    We invest in high performance healthcare companies at the convergence of technology and biology. We focus on 4 key themes: connectivity, platform innovation, payments and deep technology. This includes: distributed care, virtual care, wearables, patient empowerment, artificial intelligence, mental health and holistic care solutions, chronic disease management, data analysis, alternative drug pricing, value-based care, care efficiency, preventative medicine, synthetic biology, nanotechnology, personalized medicine, gene editing, and more
    Acrobator Ventures logo
    Acrobator Ventures is a relationship-first venture capital firm specializing in early-stage investments, particularly at the pre-seed and seed stages. The firm focuses on sectors such as B2B(2C) AI/ML software, including cybersecurity, fintech, infrastructure, synthetic media, and data-intensive technologies. Geographically, Acrobator Ventures targets founders from the Commonwealth of Independent States (CIS), the Baltics, and Central and Eastern Europe (CEE) who are building global software platforms. The firm typically invests between $200,000 and $1.25 million in initial funding, often taking a lead investor role, and continues to support companies through subsequent funding rounds (A, B, C). Acrobator Ventures brings a wealth of expertise, having built businesses themselves, led over 150 developers on SaaS and large-scale AI/ML projects, scaled a SaaS company, and invested across various regions and cultures. They emphasize founder coaching and are committed to supporting entrepreneurs throughout their journey.
    Artis Ventures (AV) logo
    Artis Ventures is a pioneering venture capital firm dedicated to investing in the convergence of technology, biology, and health—collectively termed "Tech Bio+Health." As the first fund globally to deploy capital in this transformative sector, Artis Ventures focuses on companies that leverage data, software, AI, machine learning, and deep learning to revolutionize human health and well-being. The firm coined and trademarked the term "TechBio" to signify a new era in medicine, where advancements in sequencing, computing, data management, and synthetic biology are reshaping healthcare approaches. With a global perspective, Artis Ventures aims to invest in scalable medical technologies that can improve health outcomes and cure diseases worldwide. Their portfolio includes data-driven life sciences companies addressing everyday health challenges through engineering-first approaches, personalized therapeutics, and efficient drug discovery.
    Ten VC Management, LLC is a venture capital firm specializing in pre-seed & seed stage investments. The firm focuses on scalable biomanufacturing, next-generation chemistry, biotech/techbio, synthetic biology, AI/ML for life sciences, exponential automation, advanced manufacturing and supply chains, autonomous machines and applied systems, integrated compliance, fintech/insurtech 2.0, advanced computing, big data storage and processing, transformational development tools, cybersecurity and defense, energy transition, natural resources, profitable sustainability, longevity & space tech. Ten VC Management, LLC is headquartered in United States.
    Shanghai Zhongping Capital Co. Ltd. logo
    Shanghai Zhongping Capital Co. Ltd. is a private equity and venture capital firm specializing in growth stage, expansion stage, industry consolidation, and buyout investments. It seeks to invest in the field of life science, advanced manufacturing, new material, big consumer, environmental new energy, technology, media, telecommunication, and financial services. For technology, media and telecommunications, it includes artificial intelligence, big data, fintech, 5G industry chain, enterprise services, Internet of things, and autonomous driving; For life science, it includes innovative drugs, synthetic biology, medical devices, consumer healthcare, Internet healthcare, hospital management groups, biotechnology, pharmaceutical research and development foundry; For new energy and material, this includes new energy vehicle, new power battery, photovoltaic, wind power, hydrogen energy, nuclear power, energy saving, environmental protection and frontier new materials; For advanced manufacturing, it includes robots and core components, industrial automation, aerospace, sensors, intelligent equipment, digital factories, high-end equipment manufacturing and industrial Internet; For big consumer, this includes emerging brands, cultural experience, smart logistics, digital transformation, medical beauty, healthy consumption and vertical e-commerce channels. The firm seeks to invests in China. It also invest in European and American firms that is highly associated with Greater China. The firm seeks to invests around RMB 300 million to RMB 1 billion per portfolio company. Shanghai Zhongping Capital Co. Ltd. was founded in 2016 and is based in Shanghai, China.

    Understanding Synthetic Data investors

    What are Synthetic Data investors, and what do they look for?

    Synthetic data companies have to demonstrate that models trained on generated data perform comparably to those trained on real data, and investors ask for that evidence directly. The proposition is intuitively appealing and empirically variable: synthetic data works well for some tasks and poorly for others, and companies that cannot show benchmark results on the customer's actual problem face justified scepticism. Privacy claims are the second area and they carry legal weight. Data described as synthetic may still permit inference about the individuals in the source dataset, and European supervisors have been clear that generation does not automatically remove personal data obligations. Investors want to know what privacy guarantees are offered, how they are measured and whether a data protection authority would accept the reasoning. Third, they examine whether the customer's alternative is genuinely unavailable. Companies with abundant real data have little reason to generate more, so the market concentrates where data is scarce, sensitive, expensive to label or impossible to share, and investors assess whether the target customers actually face that constraint.

    Why Synthetic Data is attracting investor interest

    Data protection obligations made sharing real data across organisational boundaries difficult, which is the constraint synthetic generation addresses most convincingly. European rules restrict transferring personal data between entities and jurisdictions, and generated datasets that preserve statistical properties without containing real individuals offer a route to collaboration that compliance would otherwise block. Regulated industries provided the clearest demand. Financial services and healthcare hold data that is valuable for model development and effectively impossible to share or move, and both face model governance requirements that demand testing on realistic data before deployment. Rare event coverage supplied a technical rather than legal argument. Training systems to handle situations that occur infrequently, whether fraud patterns, equipment failures or hazardous driving conditions, requires examples that reality supplies too rarely, and generation fills that gap. Machine learning governance obligations strengthened the case, since testing models across scenarios and demographic groups requires data that covers cases the real dataset may lack, and generated data can be constructed deliberately to include them.

    Which funding stages Synthetic Data investors are active at

    Funding follows demonstrated model performance and regulated sector adoption. Seed rounds fund the generation technology and early validation, with investors examining whether benchmark results exist against real-data baselines rather than only assessments of statistical similarity, since similarity does not guarantee downstream model performance. Series A requires paying customers in regulated industries with evidence that models trained on generated data performed acceptably in production. Investors also examine the privacy position closely, since a company whose guarantees would not satisfy a supervisor has a commercial exposure rather than a technical one. Series B and later depend on whether the product became infrastructure within customers or remained a project-based engagement, since bespoke generation for each use case produces services economics rather than software. Strategic acquirers include data platform vendors, machine learning tooling companies and testing and assurance groups. Public funding for privacy-preserving technology is available across several European programmes and suits early development.

    Types of investors active in Synthetic Data

    Data infrastructure and machine learning funds

    Investors who ask for downstream model performance against real-data baselines rather than statistical similarity measures. They know the technique works unevenly across tasks and will test whether the evidence covers the customer's actual problem.

    Privacy and compliance investors

    Capital focused on privacy-preserving technology, evaluating whether the guarantees offered would satisfy a European supervisor. Their assessment of the legal position is more useful than a technical one in this category.

    Financial services and healthcare strategics

    Corporate investors from the regulated industries where data cannot be shared or moved. They are both the natural customers and the validators, and their adoption signals to peers facing identical constraints.

    Automotive and industrial strategics

    Investors from sectors needing coverage of rare events for safety-critical systems, including autonomous driving and industrial fault detection. A technical rather than regulatory rationale with substantial budgets behind it.

    Public privacy technology funding

    European and national programmes supporting privacy-preserving data techniques, which align with regulatory policy direction. Non-dilutive and useful for early validation work.

    Ready to reach Synthetic Data investors?

    Create a free CapLink account to unlock full investor profiles, contact details, ticket sizes and intelligent matching.

    We use cookies to enhance your experience. Read our Privacy Policy